Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) fell 0.3% during trading on Tuesday . The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 421,599 shares. The stock had previously closed at $0.8317.

Oragenics Trading Up 3.2%

The firm has a market capitalization of $3.79 million, a price-to-earnings ratio of -0.07 and a beta of 1.09. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $1.01.

Institutional Trading of Oragenics

A number of institutional investors and hedge funds have recently bought and sold shares of OGEN. Bank of America Corp DE lifted its holdings in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares during the period. XTX Topco Ltd bought a new position in shares of Oragenics during the fourth quarter worth about $26,000. DRW Securities LLC lifted its stake in shares of Oragenics by 82.4% in the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after acquiring an additional 50,900 shares during the period. Sabby Management LLC bought a new stake in Oragenics in the third quarter valued at approximately $77,000. Finally, Clear Street LLC acquired a new stake in Oragenics during the 2nd quarter valued at approximately $270,000. 18.71% of the stock is currently owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.